July 08, 2024
2 min watch
Save
VIDEO: Proteolysis-targeting chimeras show promising results in prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a phase 1/phase 2 study into proteolysis-targeting chimeras in prostate cancer treatment, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, saw “encouraging” numbers in the use of the PROTAC ARV-766 in metastatic castration-resistant prostate cancer.
“In this patient population, that is quite impressive because these are heavily pretreated patients on several lines of therapy prior to this treatment, so I think it does represent a potential novel targeted strategy that may be in the pipeline in the months to years to come,” Chehrazi-Raffle said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Chehrazi-Raffle reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.